Nebivolol Ciclum

Nebivolol, the active ingredient in Nebivolol Ciclum, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nebivolol Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is used in cardiovascular therapy to control blood pressure and improve cardiac function.

Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. Heart failure: improves left‑ventricular ejection fraction and reduces symptoms in chronic heart failure.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nasal congestion. - Diarrhea or mild gastrointestinal upset. - Bradycardia: heart rate below normal limits.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Acute heart failure decompensation. - Bronchospasm in patients with reactive airway disease. - Significant liver enzyme elevation. - Allergic skin reactions such as rash or urticaria.

Before initiating therapy, clinicians should evaluate patient history and comorbidities.

Cardiovascular monitoring: assess heart rate and blood pressure regularly. Drug interactions: review concomitant medications for potential additive effects. Renal or hepatic impairment: adjust therapy based on organ function. Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. Elderly patients: start at lower doses and monitor tolerance. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nebivolol may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta‑blockers: risk of excessive β‑blockade. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Calcium channel blockers (verapamil, diltiazem): can enhance bradycardia.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypotensive effects. - Antihypertensive agents (ACE inhibitors, ARBs): additive blood pressure lowering. - Antidiabetic drugs: may mask hypoglycemia symptoms. - NSAIDs: can reduce antihypertensive efficacy. - Antidepressants (SSRIs): monitor for heart rate changes.